Detecting Alzheimer’s Early: Machine Learning’s Role in Neurological Imaging

The challenge now is making these technologies not just powerful, but practical. That means, reliable enough to support real-world care, and transparent enough for patients, families, and doctors to trust.

Want all the details? Grab your free PDF here!

Why Early Detection Needs Better Imaging Analysis

Alzheimer’s doesn’t start with memory loss. Instead, it starts silently, with microscopic changes in the brain that unfold over many years. Long before a person struggles with names or routines, there may be early shifts in brain chemistry, structure, or connectivity that go unnoticed.

But that window, the time before symptoms appear, is critical. If the disease can be identified earlier, patients and families have more time to plan, explore treatment options, join clinical trials, or take steps to protect brain health.^1,2

Traditional brain scans can help, but they have limits. Most routine imaging focuses on obvious changes, like brain shrinkage, which often appears later in the disease. What’s needed is a way to see what’s happening beneath the surface.

That’s where machine learning has been found to play a key role. These models can analyze brain images in much greater detail, finding complex patterns across many features at once. By learning how brain scans change over time, from healthy aging to mild cognitive impairment to Alzheimer’s, these tools offer a new way to detect risk and track disease progression earlier than ever before.?^1,2,3

Core Imaging Modalities for Machine Learning

When doctors look for signs of Alzheimer’s, they often start with structural MRI. These brain scans show clear images of brain anatomy and can reveal subtle shrinkage in areas like the hippocampus (regions that play a key role in memory).

When machine learning is applied to MRI data, it can detect patterns of brain atrophy that are too subtle for the human eye to notice. In fact, models trained on high-resolution MRI scans can often distinguish between healthy aging, mild cognitive impairment, and Alzheimer’s with impressive accuracy.^2,3

PET scans offer another important piece of the puzzle. While MRI looks at brain structure, PET imaging shows how the brain is functioning at a chemical level. For example, FDG-PET scans can detect areas where brain metabolism has slowed down (often an early sign of Alzheimer’s). Amyloid PET scans can pick up abnormal protein buildup. When deep learning models are applied to PET data, they’ve been able to predict progression from mild cognitive impairment to Alzheimer’s with very high sensitivity - nearly 100% in some studies.^1,4

Other types of imaging, like functional MRI (fMRI) and diffusion imaging, give insight into how different parts of the brain communicate and how white matter pathways hold up over time. These scans can add valuable detail, especially when combined with machine learning. However, they’re not yet part of routine clinical care due to challenges like long scan times and variability in how the data is collected.^5,6

Deep Learning Architectures in Neurological Imaging

Behind the scenes of early Alzheimer’s detection is a class of powerful tools called deep learning models. Specifically, convolutional neural networks (CNNs). These models are designed to recognize complex spatial patterns in brain scans, helping detect early signs of disease that are far too subtle for the human eye.

CNNs have become the backbone of many Alzheimer’s imaging studies, consistently outperforming older machine learning approaches across MRI, PET, and functional MRI data.⁵

One of the strengths of these models is how they process information. They can analyze 3D brain images as a whole or focus on carefully selected 2D slices using built-in attention mechanisms. This allows them to zero in on regions of the brain where early changes are most likely to occur.

Newer versions, inspired by transformer models, use self-attention to highlight the most relevant areas in each scan. When applied to both MRI and PET images together, some of these models have reached about 96 % accuracy in identifying early Alzheimer’s, based on data from major research initiatives like ADNI and OASIS.^2,7

Some systems go a step further by combining deep learning with traditional techniques. These hybrid models might extract specific features, like brain texture or cortical complexity, and feed that information into a deep network to improve predictions. This layered approach can help not only in identifying Alzheimer’s, but also in estimating how likely a person is to move from early symptoms to more advanced stages.^2,3

For patients, what this means is that the technology behind the scenes is becoming smarter and more precise, pushing us closer to reliable, early diagnosis that can actually impact care decisions.

Radiomics and High-Dimensional Feature Mining

Radiomics is a newer area of research that’s helping machine learning models get even more out of brain scans. Instead of just looking at overall structure, radiomics breaks down MRI or PET images into hundreds of tiny details like texture, shape, intensity, and how different parts of the brain relate to each other. These hidden features, invisible to the eye, can provide important clues about how Alzheimer’s develops.³

For example, a single brain scan might be turned into a dataset of hundreds of features from areas like the hippocampus or cortex. Machine learning models trained on this data have shown they can distinguish between healthy aging, mild cognitive impairment, and Alzheimer’s dementia with strong accuracy.

More importantly for patients, radiomics may help predict not just if someone is at risk, but how fast their symptoms might progress.

By analyzing specific features in MRI scans, researchers can identify which individuals with mild cognitive impairment are likely to convert to Alzheimer’s quickly, and which ones may remain stable for longer. Some studies have even focused on people with only subjective memory concerns, offering a way to flag high-risk individuals before clinical symptoms emerge.³

In short, radiomics gives machine learning a more detailed picture of the brain, offering the kind of fine-grained insight that could one day help tailor care to each person’s unique disease profile.

Multimodal Fusion and Disease Trajectories

Alzheimer’s doesn’t follow a single path. It’s shaped by a mix of factors, from changes in brain structure to disruptions in metabolism to a person’s genetic risk. That complexity is one reason early diagnosis is so challenging. But it’s also why researchers are developing multimodal machine learning models that bring these different pieces together into a more complete picture.

For example, combining MRI scans with genetic data has shown promising results.

Genetics can sometimes spot risk in people who appear cognitively healthy, while MRI may be better at tracking changes in those who already show mild symptoms. When these two types of data are used together, the models become better at predicting who may develop Alzheimer’s and how the disease might progress.^6,8

PET scans add another valuable layer by capturing the brain’s molecular activity. Recent deep learning models that integrate MRI and PET data have improved early detection by connecting structural changes with underlying chemical processes in the same patient. Across multiple studies, this kind of multimodal fusion has outperformed models that rely on just one type of scan, especially when it comes to identifying the earliest stages of the disease.^6,7,9

For patients and families, this means researchers are moving closer to tools that can detect Alzheimer’s earlier, more accurately and in a way that reflects the full complexity of the disease.

Novel Biomarkers: Cortical Complexity and Beyond

One of the most exciting areas of research in Alzheimer’s detection is the search for new, less obvious biomarkers (early signs of disease that go beyond traditional brain shrinkage or memory tests). With the help of machine learning, scientists are now exploring unconventional features in brain scans that could offer earlier and more precise detection.

One example is cortical complexity, which is essentially a measure of how folded and detailed the brain’s surface is.

Using a method called fractal dimension analysis, researchers can assess how this complexity changes with disease. A recent study found that machine learning models trained on these features could reliably detect Alzheimer’s, especially when combined with cognitive testing.⁹ This approach may offer a new way to catch signs of decline before more obvious structural damage appears.

Another promising area is longitudinal imaging, which involves tracking how the brain changes over time rather than looking at a single snapshot.

One study used machine learning to analyze shifts in hippocampal and ventricular volume across multiple scans. This allowed researchers to identify not just who had Alzheimer’s, but how fast their condition was progressing, helping to distinguish between normal aging, mild cognitive impairment, and Alzheimer’s disease.¹

These kinds of advanced biomarkers give hope for even earlier, more personalized insights - potentially catching the disease in its earliest stages, when interventions could make the biggest difference.

From Accuracy to Interpretability and Trust

High accuracy is important, but for machine learning tools to truly support Alzheimer’s care, they also need to be understandable and trustworthy. That’s why researchers are now focusing just as much on how these models make decisions as they are on how well they perform.

It’s not enough for an AI system to say, “This scan suggests Alzheimer’s.” Clinicians and patients need to know why.

New techniques, such as class activation mapping, help highlight the specific brain regions a model focuses on when making a prediction. In many cases, these regions line up with what we already know about Alzheimer’s, such as changes in the hippocampus, which builds confidence in the model’s reasoning.

At the same time, researchers are being cautious.

Many studies are based on data from small or carefully selected groups, which means a model might work well in one setting but fail to generalize to more diverse or real-world populations.^2,3,6 That’s why external validation (testing models on new data), and transparency around how they’re trained, is essential before they can be used safely in clinics.

This shift toward explainable AI means building systems that doctors can trust and that families can understand, so these tools can actually support care decisions rather than complicate them.

Integration into Clinical Pathways

For machine learning to make a real difference in Alzheimer’s care, it needs to fit into the day-to-day reality of how patients are diagnosed and treated. That’s why researchers are now focusing on how to bring these tools into actual clinical practice.

New systems are being built to work seamlessly with electronic health records and imaging software, so doctors can access AI-powered insights directly from the scans they already order. Some platforms generate easy-to-read risk scores that help neurologists, radiologists, and even primary care providers assess whether a patient may be in the early stages of Alzheimer’s.^3-5

In PET and nuclear medicine labs, artificial intelligence is already helping highlight brain scans with signs of Alzheimer’s, measure abnormalities in specific regions, and compare results to those of healthy individuals of the same age. These tools are designed to support - not replace - clinicians, providing a second layer of insight that can enhance the precision of diagnoses and inform discussions with patients.^3,4

Challenges, Equity, and Future Directions

Despite significant progress in machine learning for Alzheimer’s detection, real-world challenges persist, particularly in ensuring these tools are fair, accurate, and accessible to everyone.

One major issue is that brain scans can vary a lot depending on the hospital, scanner type, or patient population. Models trained on narrow or homogenous datasets may not work as well when applied to more diverse groups. This lack of representation puts some communities (particularly underserved or historically marginalized groups) at risk of less accurate or biased predictions, which could widen existing disparities in dementia diagnosis and care.^5,6

To address this, researchers are developing smarter algorithms that can adapt to different imaging conditions and patient backgrounds. They’re also building larger, more representative datasets that better reflect the full range of people affected by Alzheimer’s.^3,5

At the same time, there’s growing momentum around explainability, regulation, and collaboration.

Scientists, healthcare providers, and tech developers are working together to make sure that AI models are not only high-performing but also transparent, ethical, and clinically safe. The goal is to ensure that when these tools reach the clinic, they work for everyone and genuinely support early, equitable access to care.

For patients and families, that means a future where early detection is a reliable, inclusive part of how Alzheimer’s is diagnosed and managed.

Want to Learn More?

If you’re interested in how technology is changing the way we understand Alzheimer’s, there’s a lot happening at the intersection of brain science and artificial intelligence. Staying informed can help patients, families, and future clinicians make sense of how these tools might one day support care and decision-making.

Here are a few areas to explore:

• Differences Between Alzheimer's and Dementia
• Single-cell analysis reveals gene disruptions in early-onset Alzheimer's brain regions
• Could Sensors Help Detect Alzheimer's Disease?
• How Can We Use X-Ray Imaging to Better Understand Neurodegenerative Diseases?
• Alzheimer’s Society on the Role of Sensors in Dementia Innovation

References and Further Reading

1. Aberathne, I., Kulasiri, D., & Samarasinghe, S. (2023). Detection of Alzheimer’s disease onset using MRI and PET neuroimaging: Longitudinal data analysis and machine learning. Neural Regeneration Research, 18(10), 2134. DOI:10.4103/1673-5374.367840. https://journals.lww.com/nrronline/fulltext/2023/10000/detection_of_alzheimer_s_disease_onset_using_mri.5.aspx
2. Battineni, G., Chintalapudi, N., & Amenta, F. (2024). Machine Learning Driven by Magnetic Resonance Imaging for the Classification of Alzheimer Disease Progression: Systematic Review and Meta-Analysis. JMIR Aging, 7, e59370. DOI:10.2196/59370. https://aging.jmir.org/2024/1/e59370
3. Bevilacqua, R. et al. (2023). Radiomics and Artificial Intelligence for the Diagnosis and Monitoring of Alzheimer’s Disease: A Systematic Review of Studies in the Field. Journal of Clinical Medicine, 12(16), 5432. DOI:10.3390/jcm12165432. https://www.mdpi.com/2077-0383/12/16/5432
4. Marongiu, A. et al. (2025). Artificial Intelligence in PET Imaging for Alzheimer’s Disease: A Narrative Review. Brain Sciences, 15(10), 1038. DOI:10.3390/brainsci15101038. https://www.mdpi.com/2076-3425/15/10/1038
5. Awang, M. K. et al. (2025). Recent Advancements in Neuroimaging-Based Alzheimer's Disease Prediction Using Deep Learning Approaches in e-Health: A Systematic Review. Health Science Reports, 8(5), e70802. DOI:10.1002/hsr2.70802. https://onlinelibrary.wiley.com/doi/10.1002/hsr2.70802
6. Li, X., Qiu, Y., Zhou, J., & Xie, Z. (2021). Applications and Challenges of Machine Learning Methods in Alzheimer's Disease Multi-Source Data Analysis. Current Genomics, 22(8), 564. DOI:10.2174/1389202923666211216163049. https://www.eurekaselect.com/article/119472
7. Sener, B. et al. (2025). Improving early detection of Alzheimer’s disease through MRI slice selection and deep learning techniques. Scientific Reports, 15(1), 29260. DOI:10.1038/s41598-025-14476-0. https://www.nature.com/articles/s41598-025-14476-0
8. Mirabnahrazam, G. et al. (2022). Machine Learning Based Multimodal Neuroimaging Genomics Dementia Score for Predicting Future Conversion to Alzheimer’s Disease. Journal of Alzheimer’s Disease. DOI:10.3233_JAD-220021. https://journals.sagepub.com/doi/abs/10.3233/JAD-220021
9. Jiang, S. et al. (2024). Machine learning models for diagnosing Alzheimer’s disease using brain cortical complexity. Frontiers in Aging Neuroscience, 16, 1434589. DOI:10.3389/fnagi.2024.1434589. https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2024.1434589/full

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.